Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tac/MTX vs PTCy/Tac/MMF in RIC Allo-HCT (Progress III)
NCT03959241Phase 3Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: GVHD-free, Relapse-free Survival at 1 year. Started Jun 2019; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03959241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959241.